KYTX
NASDAQ · Biotechnology
Kyverna Therapeutics Inc
$7.94
-0.60 (-7.03%)
Financial Highlights (FY 2025)
Revenue
77.52M
Net Income
-14,424,701
Gross Margin
54.7%
Profit Margin
-18.6%
Rev Growth
+5.4%
D/E Ratio
0.25
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 54.7% | 54.7% | 54.7% |
| Operating Margin | -19.7% | -18.7% | -19.6% |
| Profit Margin | -18.6% | -15.5% | -15.7% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 77.52M | 81.06M | 62.85M |
| Gross Profit | 42.40M | 44.33M | 34.38M |
| Operating Income | -15,294,951 | -15,122,332 | -12,317,961 |
| Net Income | -14,424,701 | -12,557,463 | -9,873,224 |
| Gross Margin | 54.7% | 54.7% | 54.7% |
| Operating Margin | -19.7% | -18.7% | -19.6% |
| Profit Margin | -18.6% | -15.5% | -15.7% |
| Rev Growth | +5.4% | +22.1% | -7.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 80.87M | 71.42M | 75.37M |
| Total Equity | 329.14M | 353.67M | 302.41M |
| D/E Ratio | 0.25 | 0.20 | 0.25 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -20,391,428 | -20,108,436 | -16,996,352 |
| Free Cash Flow | -5,835,314 | -8,946,067 | -4,753,485 |